home / stock / hrmy / hrmy quote
Last: | $29.60 |
---|---|
Change Percent: | 0.95% |
Open: | $29.55 |
Close: | $29.32 |
High: | $29.865 |
Low: | $29.4012 |
Volume: | 324,749 |
Last Trade Date Time: | 04/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$29.6 | $29.55 | $29.32 | $29.865 | $29.4012 | 324,749 | 04-29-2024 |
$29.32 | $29 | $29.32 | $30.14 | $29 | 376,165 | 04-26-2024 |
$28.93 | $28.88 | $28.93 | $28.98 | $28.14 | 313,048 | 04-25-2024 |
$29.23 | $28.68 | $29.23 | $29.54 | $28.68 | 374,185 | 04-24-2024 |
$28.85 | $29.52 | $28.85 | $30 | $28.69 | 425,156 | 04-23-2024 |
$29.35 | $29.31 | $29.35 | $29.675 | $28.8 | 298,843 | 04-22-2024 |
$29.4 | $28.75 | $29.4 | $29.54 | $28.75 | 385,764 | 04-19-2024 |
$29.03 | $29.05 | $29.03 | $29.69 | $28.9 | 408,528 | 04-18-2024 |
$29.19 | $30.07 | $29.19 | $30.07 | $29.12 | 364,005 | 04-17-2024 |
$29.78 | $29.54 | $29.78 | $30.655 | $29.36 | 314,129 | 04-16-2024 |
$29.52 | $29.66 | $29.52 | $30.55 | $29.3 | 346,804 | 04-15-2024 |
$29.5 | $31.4 | $29.5 | $31.4 | $29.03 | 415,639 | 04-12-2024 |
$31.26 | $30.01 | $31.26 | $31.3 | $29.5 | 418,675 | 04-11-2024 |
$29.37 | $29.99 | $29.37 | $30.37 | $28.95 | 361,527 | 04-10-2024 |
$30.86 | $29.94 | $30.86 | $31.28 | $29.6801 | 392,475 | 04-09-2024 |
$29.84 | $30.6 | $29.84 | $30.9 | $28.63 | 985,274 | 04-08-2024 |
$30.65 | $31.29 | $30.65 | $31.33 | $30.42 | 330,741 | 04-05-2024 |
$31.23 | $31.93 | $31.23 | $32.27 | $31.15 | 340,005 | 04-04-2024 |
$31.7 | $32.71 | $31.7 | $33.66 | $31.67 | 378,746 | 04-03-2024 |
$32.7 | $32.5 | $32.7 | $32.99 | $32.13 | 285,360 | 04-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
Harmony Biosciences Holdings Inc. Company Name:
HRMY Stock Symbol:
NASDAQ Market:
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 PR Newswire PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 f...
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST TPM-1116 preclinical data suggest a potential best-in-class profile that could transform the treatment of narcolepsy and other sleep/wake...
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME Trial initiation a step toward potentially treating excessive daytime sleepiness and behavioral symptoms in patients with PWS PR Newswire ...